Cargando…
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
SIMPLE SUMMARY: The antimalarial drug artesunate also has anticancer activity. Based on what is known about how artesunate works in malaria, we hypothesized that the kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which is often mutated in non-...
Autores principales: | Hill, Kristen S., McDowell, Anthony, McCorkle, J. Robert, Schuler, Erin, Ellingson, Sally R., Plattner, Rina, Kolesar, Jill M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070990/ https://www.ncbi.nlm.nih.gov/pubmed/33920029 http://dx.doi.org/10.3390/cancers13081885 |
Ejemplares similares
-
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
por: McDowell, Anthony, et al.
Publicado: (2021) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021) -
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021) -
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020) -
Human macrophage-engineered vesicles for utilization in ovarian cancer treatment
por: Schweer, David, et al.
Publicado: (2023)